EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Decoding the tumor immune landscape: emerging TIL subsets as prognostic biomarkers and therapeutic targets

Rahaman Shaik, Sai Abhistika Royyala, Bhanu Inapanuri, Syeda Fatima Sarwar, Shaheen Mahira, Shaik Azeeza

Naunyn-Schmiedeberg's Archives of Pharmacology · 2026

DOI: 10.1007/s00210-025-04913-2 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Naunyn-Schmiedeberg's Archives of Pharmacology, 2026. Verfasst von Rahaman Shaik und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi, 110062, India. shaikrahaman_sch@jamiahamdard.a…. Hauptthemen laut MEDLINE: Lymphocytes, Tumor-Infiltrating, Neoplasms, Biomarkers, Tumor. Die Arbeit nennt 111 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Tumor -infiltrating lymphocytes (TILs) play a pivotal role in cancer immunity, with CD3 + T cells and CD8 + cytotoxic T cells historically regarded as key prognostic markers. Other TIL subsets are CD4 + T helper cells, regulatory T cells (Tregs), tissue-resident memory T cells (TRM cells), and non-traditional T cell populations like γδ T cells and innate-like T cells. These subsets have diverse roles which influence the disease duration and immunotherapy mechanism, from immune evasion to tumor suppression. TRM cells which are recognized by the expression of CD103 and CD69 are linked with better survival and enhance tumor management, while Tregs function mainly in the tumor microenvironment (TME). Additionally, γδ T cells have strong anti-cancer activity. Developments in single-cell sequencing and spatial transcriptomics have improved the understanding of TIL heterogeneity and their functional states, enhancing their prognostic and therapeutic significance. Understanding how different expanded TIL subgroups impact treatment response helps to recognize new biomarkers and therapeutic targets. This review investigates functions of TIL populations beyond the traditional markers like CD3 and CD8 across different cancers while concentrating on predictive outcomes in immunotherapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lymphocytes, Tumor-InfiltratingNeoplasmsBiomarkers, TumorHumansAnimalsPrognosisTumor MicroenvironmentImmunotherapy

Stichwörter der Autor:innen

CD3CD4CD8PrognosisTumor infiltrating lymphocytes

Substanzen

Biomarkers, Tumor

Autor:innen und Institutionen

  • Department of Pharmacology, School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi, 110062, India. shaikrahaman_sch@jamiahamdard.ac.in.
  • Department of Pharmacology, St. Pauls College of Pharmacy, Dist. Ranga Reddy, Hyderabad, 501510, Telangana State, India. shaikrahaman_sch@jamiahamdard.ac.in.
  • Research & Development Department, KVB Asta Life Sciences, Hyderabad, India. shaikrahaman_sch@jamiahamdard.ac.in.
  • Research & Development Department, Idaib Health, 709 Havens Dr, Windsor, ON, N9G 2S9, Canada. shaikrahaman_sch@jamiahamdard.ac.in.
  • Department of Pharmacology, St. Pauls College of Pharmacy, Dist. Ranga Reddy, Hyderabad, 501510, Telangana State, India.
  • Department of Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh, Pittsburgh, PA, 15213, USA.

Zitieren

APA

Shaik, R., Royyala, S. A., Inapanuri, B., Sarwar, S. F., Mahira, S., & Azeeza, S. (2026). Decoding the tumor immune landscape: emerging TIL subsets as prognostic biomarkers and therapeutic targets. Naunyn-Schmiedeberg's Archives of Pharmacology. https://doi.org/10.1007/s00210-025-04913-2

Vancouver

Shaik R, Royyala SA, Inapanuri B, Sarwar SF, Mahira S, Azeeza S. Decoding the tumor immune landscape: emerging TIL subsets as prognostic biomarkers and therapeutic targets. Naunyn-Schmiedeberg's Archives of Pharmacology. 2026. doi:10.1007/s00210-025-04913-2

BibTeX
@article{Shaik2026,
  author = {Shaik, Rahaman and Royyala, Sai Abhistika and Inapanuri, Bhanu and Sarwar, Syeda Fatima and Mahira, Shaheen and Azeeza, Shaik},
  title = {Decoding the tumor immune landscape: emerging TIL subsets as prognostic biomarkers and therapeutic targets},
  journal = {Naunyn-Schmiedeberg's Archives of Pharmacology},
  year = {2026},
  doi = {10.1007/s00210-025-04913-2}
}
Kostenlos starten →